Main Classes of Diabetes Medications
The major classes of diabetes medications include biguanides (metformin), SGLT2 inhibitors, GLP-1 receptor agonists, dual GIP/GLP-1 agonists, DPP-4 inhibitors, sulfonylureas, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, and insulins 1, 2.
Functional Classification Framework
Diabetes medications can be organized by their mechanism of action into three functional categories 3:
1. Insulin Providers (Increase Insulin Supply)
- Exogenous Insulin: NPH insulin, long-acting analogs (glargine U-100, U-300, detemir, degludec) 1
- Direct Insulin Secretagogues:
- Incretin-Based Therapies (glucose-dependent insulin secretion):
2. Insulin Sensitizers (Improve Insulin Action)
- Biguanides: metformin (reduces hepatic glucose production, improves peripheral insulin sensitivity) 2, 3
- Thiazolidinediones (TZDs): improve insulin action, reduce insulin resistance 1, 2
3. Insulin-Independent Agents (Work Outside Insulin Pathways)
- SGLT2 inhibitors: prevent renal glucose reabsorption 1, 3
- Alpha-glucosidase inhibitors: delay intestinal carbohydrate absorption 2, 3
- Amylin analogs: modulate gastric emptying and glucagon secretion 2
Weight and Metabolic Effects: Critical Considerations
Medications that promote weight loss should be prioritized in patients with obesity (>90% of type 2 diabetes patients) 1:
Highest Efficacy for Weight Loss and Glucose Control:
- Tirzepatide and semaglutide (most effective) 1
- Dulaglutide, liraglutide, extended-release exenatide (moderate effect) 1
Weight Neutral or Modest Benefit:
- Metformin, SGLT2 inhibitors, DPP-4 inhibitors 1
Promote Weight Gain (Use Judiciously at Lowest Dose):
- Insulins, sulfonylureas, thiazolidinediones 1
Cardiovascular and Renal Protection
SGLT2 inhibitors and GLP-1 receptor agonists provide cardiovascular and kidney protective benefits beyond glucose lowering 5. The non-steroidal mineralocorticoid receptor antagonist finerenone also demonstrates cardiovascular and kidney protection 5.
Common Pitfalls
Overbasalization with insulin occurs when basal insulin doses exceed clinically necessary levels, masking insufficient mealtime coverage. Warning signs include 1:
- Bedtime-to-morning glucose differential ≥50 mg/dL (≥2.8 mmol/L)
- Hypoglycemia (aware or unaware)
- High glucose variability
When switching between basal insulins, doses typically convert unit-for-unit, but consider 10-20% dose reduction for patients in tight control or at high hypoglycemia risk, particularly when switching from detemir or U-300 glargine 1.